How are KRYS long call max profit and max loss calculated?

Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the KRYS long call priced from the end-of-day chain at a 30-day expiry (ATM IV 40.10%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$1,360.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.

What is the breakeven for a KRYS long call?

The breakeven for the KRYS long call priced on this page is roughly $383.60 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current KRYS market-implied 1-standard-deviation expected move is approximately 11.50%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.

How does current KRYS implied volatility affect this long call?

KRYS ATM IV is at 40.10% with IV rank near 16.14%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.

KRYS Long Call Strategy

KRYS (Krystal Biotech, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.

KRYS (Krystal Biotech, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $10.97B, a trailing P/E of 48.45, a beta of 0.53 versus the broader market, a 52-week range of 130.5-376.28, average daily share volume of 299K, a public-listing history dating back to 2017, approximately 275 full-time employees. These structural characteristics shape how KRYS stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 0.53 indicates KRYS has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure. The trailing P/E of 48.45 is on the rich side, which tends to correlate with higher earnings-window IV expansion as the market debates whether forward growth supports the multiple.

What is a long call on KRYS?

A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.

Current KRYS snapshot

As of June 30, 2026, spot at $369.29, ATM IV 40.10%, IV rank 16.14%, expected move 11.50%. The long call on KRYS below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 17-day expiry.

Why this long call structure on KRYS specifically: KRYS IV at 40.10% is on the cheap side of its 1-year range, which favors premium-buying structures like a KRYS long call, with a market-implied 1-standard-deviation move of approximately 11.50% (roughly $42.45 on the underlying). The 17-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated KRYS expiries trade a higher absolute premium for lower per-day decay. Position sizing on KRYS should anchor to the underlying notional of $369.29 per share and to the trader's directional view on KRYS stock.

KRYS long call setup

The KRYS long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With KRYS near $369.29, the first option leg uses a $370.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed KRYS chain at a 17-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 KRYS shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$370.00	$13.60

KRYS long call risk and reward

Net Premium / Debit: -$1,360.00
Max Profit (per contract): Unbounded
Max Loss (per contract): -$1,360.00
Breakeven(s): $383.60
Risk / Reward Ratio: Unbounded

Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.

KRYS long call payoff curve

Modeled P&L at expiration across a range of underlying prices for the long call on KRYS. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

P&L at expiration across the modeled underlying-price range. Green shading marks profitable regions, red shading marks loss regions. Dotted purple verticals mark breakevens; the solid dark vertical marks current spot.

Underlying Price	% From Spot	P&L at Expiration
$0.01	-100.0%	-$1,360.00
$81.66	-77.9%	-$1,360.00
$163.31	-55.8%	-$1,360.00
$244.96	-33.7%	-$1,360.00
$326.61	-11.6%	-$1,360.00
$408.26	+10.6%	+$2,466.48
$489.92	+32.7%	+$10,631.57
$571.57	+54.8%	+$18,796.67
$653.22	+76.9%	+$26,961.76
$734.87	+99.0%	+$35,126.86

When traders use long call on KRYS

Long calls on KRYS express a bullish thesis with defined risk; traders use them ahead of KRYS catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.

KRYS thesis for this long call

The market-implied 1-standard-deviation range for KRYS extends from approximately $326.84 on the downside to $411.74 on the upside. A KRYS long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current KRYS IV rank near 16.14% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on KRYS at 40.10%. As a Healthcare name, KRYS options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to KRYS-specific events.

KRYS long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. KRYS positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move KRYS alongside the broader basket even when KRYS-specific fundamentals are unchanged. Long-premium structures like a long call on KRYS are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current KRYS chain quotes before placing a trade.

Frequently asked questions

What is a long call on KRYS?: A long call on KRYS is the long call strategy applied to KRYS (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With KRYS stock trading near $369.29, the strikes shown on this page are snapped to the nearest listed KRYS chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are KRYS long call max profit and max loss calculated?: Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the KRYS long call priced from the end-of-day chain at a 30-day expiry (ATM IV 40.10%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$1,360.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a KRYS long call?: The breakeven for the KRYS long call priced on this page is roughly $383.60 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current KRYS market-implied 1-standard-deviation expected move is approximately 11.50%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a long call on KRYS?: Long calls on KRYS express a bullish thesis with defined risk; traders use them ahead of KRYS catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
How does current KRYS implied volatility affect this long call?: KRYS ATM IV is at 40.10% with IV rank near 16.14%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.